{"transactions":[{"id":1839264,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":111691,"kind":"person","name":"Gutfreund John Peter","position":1,"cik":"0001940797","reported_name":"Gutfreund John Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Warrants to Purchase Common Stock","published_at":"2023-07-03T22:00:08.000Z","date":"2023-06-30","kind":"other","planned":false,"acquired":false,"shares":3564728,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"Represents warrants to purchase shares of Common Stock (the \"Warrants\") that were distributed by the Halle Fund on a pro rata basis to its members (the \"Halle Warrant Distribution\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The Warrants are currently exercisable, subject to a beneficial ownership limitation of 4.99%."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise, the beneficial owner of any securities covered by this statement. The Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of the Reporting Person in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Represents Warrants directly beneficially owned by the Halle Fund. The Reporting Person is the investment manager and a control person of Halle Capital Partners GP LLC, the managing member of the Halle Fund. In such capacity, the Reporting Person may be deemed to beneficially own any securities directly owned by the Halle Fund."}],"balance_after":0,"derivative":{"exercise_price":1.53,"expiration_date":"2027-04-19","underlying":"Common Stock","underlying_shares":3001876},"source":{"system":"sec-edgar","filing":"0000899243-23-016837","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1642380/000089924323016837/doc4.xml","form_type":"4"}},{"id":1839263,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":111691,"kind":"person","name":"Gutfreund John Peter","position":1,"cik":"0001940797","reported_name":"Gutfreund John Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Common Stock, no par value","published_at":"2023-07-03T22:00:08.000Z","date":"2023-06-30","kind":"other","planned":false,"acquired":false,"shares":3085047,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Common Stock of Oncocyte Corporation (the \"Issuer\"), no par value (the \"Common Stock\"), that were distributed by Halle Special Situations Fund LLC (the \"Halle Fund\") on a pro rata basis to its members (the \"Halle Common Stock Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of Common Stock directly beneficially owned by the Halle Fund. John Peter Gutfreund (the \"Reporting Person\") is the investment manager and a control person of Halle Capital Partners GP LLC, the managing member of the Halle Fund. In such capacity, the Reporting Person may be deemed to beneficially own any securities directly owned by the Halle Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise, the beneficial owner of any securities covered by this statement. The Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of the Reporting Person in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-016837","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642380/000089924323016837/doc4.xml","form_type":"4"}},{"id":1924543,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":111691,"kind":"person","name":"Gutfreund John Peter","position":1,"cik":"0001940797","reported_name":"Gutfreund John Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2023-04-06T01:30:30.000Z","date":"2023-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":588.2353,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The 588.2353 shares of Series A Convertible Preferred Stock (the \"Series A Shares\") held by the Reporting Person were convertible into 384,470 shares of Common Stock, at a conversion price of $1.53 per share, subject to a beneficial ownership limitation of 4.99%, on April 8, 2024 or the earlier of occurrence of certain events or transactions specified in a purchase agreement by and among the Issuer, the Reporting Person, and certain other parties thereto (the \"Purchase Agreement\"). On April 3, 2023, the Issuer redeemed all of the Series A Shares for a cash payment of $618,672.34 calculated in accordance with the terms of the Purchase Agreement. The redemption of the Series A Shares was approved by the board of directors of the Issuer pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended."},{"field":"shares","element":"transactionShares","label":"F2","text":"The 588.2353 shares of Series A Convertible Preferred Stock (the \"Series A Shares\") held by the Reporting Person were convertible into 384,470 shares of Common Stock, at a conversion price of $1.53 per share, subject to a beneficial ownership limitation of 4.99%, on April 8, 2024 or the earlier of occurrence of certain events or transactions specified in a purchase agreement by and among the Issuer, the Reporting Person, and certain other parties thereto (the \"Purchase Agreement\"). On April 3, 2023, the Issuer redeemed all of the Series A Shares for a cash payment of $618,672.34 calculated in accordance with the terms of the Purchase Agreement. The redemption of the Series A Shares was approved by the board of directors of the Issuer pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The 588.2353 shares of Series A Convertible Preferred Stock (the \"Series A Shares\") held by the Reporting Person were convertible into 384,470 shares of Common Stock, at a conversion price of $1.53 per share, subject to a beneficial ownership limitation of 4.99%, on April 8, 2024 or the earlier of occurrence of certain events or transactions specified in a purchase agreement by and among the Issuer, the Reporting Person, and certain other parties thereto (the \"Purchase Agreement\"). On April 3, 2023, the Issuer redeemed all of the Series A Shares for a cash payment of $618,672.34 calculated in accordance with the terms of the Purchase Agreement. The redemption of the Series A Shares was approved by the board of directors of the Issuer pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The 588.2353 shares of Series A Convertible Preferred Stock (the \"Series A Shares\") held by the Reporting Person were convertible into 384,470 shares of Common Stock, at a conversion price of $1.53 per share, subject to a beneficial ownership limitation of 4.99%, on April 8, 2024 or the earlier of occurrence of certain events or transactions specified in a purchase agreement by and among the Issuer, the Reporting Person, and certain other parties thereto (the \"Purchase Agreement\"). On April 3, 2023, the Issuer redeemed all of the Series A Shares for a cash payment of $618,672.34 calculated in accordance with the terms of the Purchase Agreement. The redemption of the Series A Shares was approved by the board of directors of the Issuer pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Reporting Person previously misreported on his Form 3 filed with the Securities and Exchange Commission on August 8, 2022 the number of Series A Shares he owned due to an administrative error. As of the date of that Form 3 filing, the Reporting Person owned 588.2353 Series A Shares, not the 1,176.48 Series A Shares reported. Following the disposition of 588.2353 Series A Shares reported here, the Reporting Person does not own any Series A Shares."}],"balance_after":0,"derivative":{"exercise_price":1.53,"expiration_date":"2024-04-08","underlying":"Common Stock, no par value","underlying_shares":384470},"source":{"system":"sec-edgar","filing":"0001493152-23-011106","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223011106/ownership.xml","form_type":"4"}},{"id":1924542,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":111691,"kind":"person","name":"Gutfreund John Peter","position":1,"cik":"0001940797","reported_name":"Gutfreund John Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, no par value","published_at":"2023-04-06T01:30:30.000Z","date":"2023-04-03","kind":"grant","planned":false,"acquired":true,"shares":1000000,"price":0.3544,"value":354400.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares of the Issuer's common stock, no par value (\"Common Stock\"), are held by Newtown Road 130 Holdings LLC (\"Newtown\"). The Reporting Person is the Managing Member of Newtown and in such capacity has the right to vote and dispose of securities held by Newtown."}],"balance_after":1075000,"source":{"system":"sec-edgar","filing":"0001493152-23-011106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223011106/ownership.xml","form_type":"4"}},{"id":1924541,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":111691,"kind":"person","name":"Gutfreund John Peter","position":1,"cik":"0001940797","reported_name":"Gutfreund John Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, no par value","published_at":"2023-04-06T01:30:30.000Z","date":"2023-04-03","kind":"grant","planned":false,"acquired":true,"shares":705000,"price":0.3544,"value":249852.0,"ownership":{"direct":true},"balance_after":715000,"source":{"system":"sec-edgar","filing":"0001493152-23-011106","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223011106/ownership.xml","form_type":"4"}},{"id":2075380,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":111691,"kind":"person","name":"Gutfreund John Peter","position":1,"cik":"0001940797","reported_name":"Gutfreund John Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, no par value","published_at":"2022-12-28T21:05:38.000Z","date":"2022-12-23","kind":"purchase","acquired":true,"shares":75000,"price":0.3297,"value":24727.5,"ownership":{"direct":false,"nature":"see footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price of $0.3297 per share represents a weighted average of prices ranging from $0.31 to $0.33 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares of common stock are held by Newtown Road 130 Holdings LLC. The Reporting Person is the Managing Member of Newtown Road 130 Holdings LLC and in such capacity has the right to vote and dispose of the securities held by such entity."}],"balance_after":75000,"source":{"system":"sec-edgar","filing":"0001493152-22-036653","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315222036653/ownership.xml","form_type":"4"}},{"id":2180634,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":111691,"kind":"person","name":"Gutfreund John Peter","position":1,"cik":"0001940797","reported_name":"Gutfreund John Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2022-08-18T00:19:20.000Z","date":"2022-08-15","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders."}],"balance_after":45000,"derivative":{"exercise_price":0.97,"expiration_date":"2032-08-15","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001493152-22-023380","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315222023380/ownership.xml","form_type":"4"}},{"id":2180633,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":111691,"kind":"person","name":"Gutfreund John Peter","position":1,"cik":"0001940797","reported_name":"Gutfreund John Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, no par value","published_at":"2022-08-18T00:19:20.000Z","date":"2022-08-15","kind":"purchase","acquired":true,"shares":25000,"price":0.93,"value":23250.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price of $0.93 per share represents a weighted average of prices ranging from $0.91 to $0.97 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held by the minor children of the Reporting Person, and the Reporting Person has voting and dispositive control over such securities."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001493152-22-023380","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315222023380/ownership.xml","form_type":"4"}},{"id":2180632,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":111691,"kind":"person","name":"Gutfreund John Peter","position":1,"cik":"0001940797","reported_name":"Gutfreund John Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, no par value","published_at":"2022-08-18T00:19:20.000Z","date":"2022-08-15","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001493152-22-023380","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315222023380/ownership.xml","form_type":"4"}}]}